Results: 24% of patients with previous cerebrovascular disease were not on anti-thrombotic medication at the time of admission. Nine percent of appropriate patients were not taking anti-thrombotic medication at discharge. Patients left with moderate to very severe disability (Barthel scores 14 or less) compared with those independent with mild disability (Barthel score 15-20) were more likely not to have anti-thrombotic treatment (18% versus 8%). Fifty-four percent of patients with known hyperlipidaemia and 21% of those with previous ischaemic heart disease were on lipid lowering therapy on admission. Sixty-four percent of patients had lipids measured during their hospital stay and of those with high total cholesterol or LDL the rate of non-treatment was 36%. Older patients (75+ years) were less likely to be treated (54%) than those <65 years (71%). Seventy-nine percent of known patients with hypertension were on treatment at admission, with 78% being treated by discharge from hospital. At 6 months after stroke a systolic blood pressure of 140 mmHg or less, and a diastolic of 85 mmHg or less, was achieved in 41% of known pre-stroke hypertensives on treatment, 31% of previously untreated hypertensives but on treatment at follow-up and 40% of patients not previously labelled as hypertensive. Conclusions: major deWciencies in delivery of secondary prevention after stroke have been demonstrated. Services need reorganisation to prevent unnecessary mortality and morbidity in this group of patients.
Introduction
The incidence of stroke in the United Kingdom is about 130,000 per year, of whom 10-15% will have a recurrence within 1 year and 30% within 5 years [1, 2] . Randomised controlled trials have shown that secondary prevention is clearly beneWcial in ischaemic stroke. The meta-analysis of the Antithrombotic Trialists' Collaboration demonstrated a 23% risk reduction in vascular events for patients receiving antithrombotic medication [3] . Up to 50% reduction in stroke recurrence can be achieved using anticoagulants in patients with non-rheumatic atrial Wbrillation [4] and a 22-28% risk reduction using long acting angiotensin converting enzyme inhibitors even in people with 'normal' blood pressure [5, 6] . The Heart Protection Study has also suggested that lipid lowering therapy after stroke is beneWcial [7] . The National Clinical Guidelines for stroke [8] therefore state with level A strength of recommendation that (i) all patients with ischaemic stroke should be treated with anti-thrombotic medication; (ii) patients with non rheumatic atrial Wbrillation should be considered for anticoagulation; (iii) patients should have their blood pressure controlled according to British Hypertension Society Guidelines and then consideration be given to starting a long acting ACE inhibitor and thiazide diuretic; (iv) patients with a history of ischaemic heart disease and total cholesterol of >5 mmol/l should be treated with a statin. (This guideline predated the publication of the Heart Protection Study).
This paper uses data collected for the National Sentinel Audit of Stroke in England, Wales and Northern Ireland 2001-2002 to identify how effectively the National Guidelines were being implemented.
Methods

Sample
All hospitals treating acute stroke in England, Wales, Northern Ireland, the Channel Islands and the Isle of Man were invited to participate in the audit. Patients who had been classiWed with a primary diagnosis of stroke according to the World Health Organisation International Statistical ClassiWcation of Diseases and Related Health Problems (10th Revision) coding system (ICD10 codes I61, I63 or I64) admitted to a hospital between 1 April 2001 and 30 June 2001 were included. Auditors were instructed to obtain a minimum of 20 and a maximum of 40 consecutive admissions from each institution over the audit time frame.
Data collection
Data were collected retrospectively from hospital and general practitioner records, covering the period from admission to 6 months after discharge. Data were retrieved from the clinical notes of all disciplines involved, anonymised and sent to the Royal College of Physicians for analysis. The audit tool had been developed by the Intercollegiate Stroke Working Party and piloted before use [9] . Data were collected on all aspects of care.
This report concentrates on issues related to secondary prevention including:
Previous co-morbidity: i.e. atrial Wbrillation, previous cerebrovascular disease, diabetes mellitus, hyperlipidaemia, hypertension, ischaemic heart disease, peripheral vascular disease and valvular heart disease.
Hypertension: medication pre-admission, in-hospital blood pressure, ('has the blood pressure been recorded as above 140 mmHg systolic or 85 diastolic on more than three occasions?') treatment of hypertension in hospital, blood pressure 4-8 months after stroke and use of anti-hypertensive drugs 4-8 months post stroke.
Anti-thrombotic treatment: medication pre-admission, at discharge and at 4-8 months post stroke. Use of anticoagulants for patients in atrial Wbrillation.
Lipid management : medication pre-admission, measurement of cholesterol and level, prescription of lipid lowering agents during in-patient stay and at follow-up.
For each question the options were 'Yes', 'No' or 'No but . . .' enabling the auditor to identify where patients met predeWned speciWc criteria that signiWed that the standard was not appropriate in that instance. The data auditors were members of the healthcare team (including doctors, nurses and members of the professions allied to medicine) and clinical audit departments within trusts. The Wrst Wve cases were audited twice by different auditors working independently.
Analysis and reporting
Statistical analyses were performed using the statistical software package SPSS. Data were analysed with the 'no but . . .' responses excluded from the denominator. The ever changing denominators within the results reXect not only the 'No, but . . .' options but also the fact that for all questions there were some missing data. The 'No, but . . .' options were used throughout the patient audit to indicate that standards were not applicable in some patients for good reasons. The question about whether the patient was on anti-thrombotic medication by the time of discharge had a 'No but . . .' option that was relevant if the patient had died or had had a intra-cerebral haemorrhage. (3, 816) were male (mean age 73 years), and 53% (4,358) were female (mean age 79 years). Mortality at 7 days was 12% (975), at 30 days, 24% (1961) and total in-patient mortality 29% (2411). Sixty-six percent (5, 447) were ischaemic infarcts, 12% (990) haemorrhage, 4 % (325) haemorrhagic infarct and 18% (1,438) were unclassiWed. An overall summary of the audit is available [10] . For 5,771 patients discharged from hospital follow-up data was obtained from 72% (4, 170) . This includes partial follow-up as well as complete follow-up for all questions and reXects the difWculty in obtaining post-discharge data from general practices. For this reason the follow-up has been reported in less detail than for during the admission.
One hundred and thirty-six sites (58%) submitted 652 duplicate cases for the inter rater study which were pooled together for analysis by item. The results showed good reliability with most items having a kappa coefWcient of agreement of over 0.60. For the eight co-morbidity items the kappa statistics ranged from 0.68-0.89, median 0.79. For whether the patient was on medication before admission, kappa was 0.87. For 11 speciWc antihypertensive, antithrombotic and lipid lowering drugs before admission kappa ranged from 0.76-0.98, median 0.90; during admission from 0.57-0.95, median 0.80; at follow-up from 0.48-0.96, median 0.80.
Comorbidity
Previously documented risk factors for stroke were known in 7,905 cases. Hypertension was documented in 46% (3,598), previous cerebrovascular disease in 32% (2,545), myocardial infarction in 21% (1,623), atrial Wbrillation in 18% (1,417), diabetes mellitus in 14% (1,138), hyperlipidaemia in 9% (741), peripheral vascular disease in 4% (353) and valvular heart disease in 2% (193) . No comorbidity was documented for 22% (1,726) whilst 18% (1,403) had three or more types.
Antithrombotic treatment
Of 7,884 patients whose pre-admission medication was known 46% (3,666) were taking an anti-thrombotic drug. Overall 36% (2,799) were on aspirin alone, 6% (443) were on warfarin or another anticoagulant alone, and 4% (424) were on others including combinations. Of 2,496 patients who were recorded as having had previous stroke or TIA 76% (1,904) were on anti-thrombotic drugs.
Anti-thrombotic therapy was given by the time of discharge in 91% (4,583/5,020) of applicable patients. Treatment rates were 92% for those with a previous history of cerebrovascular disease, 93% for those with ischaemic heart disease and 94% for those with peripheral vascular disease ( Table 1) . Discharged patients over 75 years, previously institutionalised, and with moderate to severe functional disability were less likely to be treated with anti-thrombotics by discharge. The treatment rate was 82% for patients with a pre-stroke Barthel score of under 15 as compared to 92% for patients with scores of 15-20. The inpatient treatment rate for discharged patients who had spent some time in a stroke unit was 94% (1,963/2,077). This compares to 89% (2,516/2,825) for discharged patients who had not spent time in a stroke unit (P < 0.001).
At follow-up there were 3,612 patients whose medication was known. Seven hundred and ninety (22%) were not on anti-thrombotic treatment, and 523 of these had good reason not to be (i.e. patient had intra-cerebral haemorrhage or it was documented that anti-thrombotic treatment was contra-indicated). Thus of the patients to whom the standard applied 91% (2,822/3,089) were on treatment.
There were 2,799 patients admitted on aspirin alone. At follow-up 94% (993/1,052) were on an anti-thrombotic; 47% (497/1,052) were still on aspirin alone, 11% (111) on warfarin/other anticoagulant alone, 7% (70) clopidogrel alone, 19% (200) on aspirin with dipyridimole, 3% (27) dipyridamole alone, 2% (20) aspirin and warfarin, 2% (22) aspirin and clopidogrel, 4% (46) were on less common combinations, whilst 6% (59) were not on therapy.
Lipid lowering agents
Of 7,884 patients with known pre-admission medication status, 9% (715) were on lipid lowering agents. Almost all of these (671/715) were reported to be on statins alone, with 23 on Wbrates alone, 4 on anion-exchange resins alone, 8 on other classes of agent alone and 3 on combinations involving statins and Wbrates. The treatment rate was 54% (397/732) for patients with known hyperlipidaema, 57% (290/511) with hypertension and hyperlipidaemia, 23% (140/298) with hypertension and diabetes, 21% (339/1587) with previous ischaemic heart disease and 12% (309/2,496) with previous cerebrovascular disease.
A blood cholesterol measurement was documented for 64% (3,709/5,782) of patients for whom the standard applied during their admission. Hyperlipidaemia status (>5.0 total or LDL >3 mmol/l) was known for 3,631/3,709 and Patients with a history of hyperlipidaemia, patients under 75 years and patients with more independent pre-stroke function were more likely to be receiving lipid lowering therapy before their admission (Table 2 ) and also during their admission if in hospital they were diagnosed with hyperlipidaemia. The inpatient treatment rate for patients with hyperlipidaemia who had spent some time in a stroke unit was 95% (1,923/ 2,034). This compares to 89% (2,442/2,741) for patients who had not spent time in a stroke unit (P < 0.001).
Anti-hypertensive treatment
Of 7,884 patients with known admission medication 36% (2,807) were reported to be taking anti-hypertensive drugs. The types of drug most in use were beta blocker (1,086), calcium channel blocker (945), thiazide diuretic (895), ACE inhibitor (884), alpha blocker (189) and angiotensin-II receptor antagonists (189). Of those with hypertension before admission 79% (2,807/3,532) were on blood pressure lowering drugs. Of those with hypertension and diabetes 85% (507/598) were taking medication and 83% (424/511) of those with hypertension and hyperlipidaemia were treated. Anti-hypertensives were prescribed by discharge for 78% (2,414/3,079) of those recorded as having raised blood pressure during admission.
Anti-hypertensive treatment was more often prescribed at presentation and as an in-patient for those with greater comorbidity, younger patients, those previously institutionalised and those with better pre-stroke function ( Table 3) . The inpatient treatment rate for patients with diagnosed hypertension and who had spent some time in a stroke unit was 82% (1,029/1,251) . This compares to 76% (1,338/1,761) for patients who had not spent time in a stroke unit (P<0.001).
For those diagnosed as hypertensive and receiving drugs as an inpatient (2,414) the types of drugs used during admission were ACE inhibitor (36%, 869), calcium channel blocker (33%, 786), beta blocker (32%, 779), thiazide diuretic (32%, 780), alpha blocker (6%, 135), angiotensin-II receptor antagonists (5%, 110), and other drugs (8%, 188). In 61% (1,483/2,414) a single type of drug was used (ACE inhibitor 17%, beta blocker 13%, calcium channel 13%, thiazide 12%), whilst for 28% (676) two types were used, and for 11% (255) three or more types were used. Follow-up data on anti-hypertensive treatment was available for 3,404 patients. These included 1,091 discharged patients with a history of hypertension and on antihypertensives before admission, of whom 84% (915) were still taking anti-hypertensives at follow up. Of this group of 915 who were still on treatment 785 had blood pressure recordings at follow-up and of these 41% (320/785) were normotensive. There were also 245 discharged patients with a history of hypertension before admission but who were untreated and of these 68% (167/245) had started therapy by follow-up. Of this group 31% (45/145) were normotensive. Also of 1,128 discharged patients not previously known to be hypertensive 47% (531) were on treatment at follow-up and 40% (186/463) of this group were normotensive at follow-up.
Lifestyle advice
There was documentation of advice provided during admission about avoidance of risk factors for further stroke (smoking, alcohol consumption etc) in 37% (1,757/4,721) of cases. For those followed-up at 4-8 months 22% (831/ 3,698) had been smokers at the time of stroke and of these 61% (326/533) were still smoking at follow-up.
Discussion
This study is the largest audit of stroke prevention ever conducted in the United Kingdom and describes the current practice for secondary prevention of patients hospitalised after stroke. The 95% participation rate of hospitals collecting consecutive cases of stroke and the large overall numbers mean that these data are likely to be a realistic picture of current practice in the UK. Instructions to auditors to use consecutive admissions should have overcome the problems of unrepresentative patient selection, however this may have been a problem from some sites. The case mix measures for the 8200 patients included are similar to those reported previously for other hospitalised samples [11] suggesting that overall there was not biased reporting of cases. Hospitalised stroke patients receive better quality of care than non-admitted patients and therefore the Wgures achieved in our series may be better than would be obtained from a population-based sample [12] . There must be concern that retrospective data collection from case notes Wnds only what was recorded and not the treatment actually received. However not only is medication recorded in the medical notes but it is also recorded on the prescription charts. The repeatability of the data collected in duplicate in this study is comparatively higher than for many process measures collected in previous audits of stroke and for other audit studies elsewhere [13] . The primary care data does need to be treated with caution; only between 60 and 70% of data items were completed which may have introduced bias and it is possible that patients were taking over the counter medication, particularly aspirin, without the general practitioner being aware of it.
Stroke remains an important cause of death in developed countries and prevention of stroke has been made a priority in national health strategy in the United Kingdom [14, 15] . Because of the high recurrence rate, secondary prevention is a clear target, but previous studies of the effectiveness of secondary prevention after stroke have been limited. A prospective population based study found major deWcits in delivery of care, with 24.4% of appropriate patients not receiving anti-platelet medication, 59.4% not receiving anticoagulants and 29.5% not receiving anti-hypertensive medication 3 months after ischaemic stroke [12] . Data from the 1998 National Sentinel Stroke Audit [16] showed that 88% of appropriate patients discharged after ischaemic stroke were taking aspirin 6 months later. Studies of preventative treatment after myocardial infarction also showed sub-optimal use after discharge from hospital [17, 18] .
Clearly there are major opportunities being missed in both primary and secondary stroke prevention. From previous national audit data it would appear as if little has changed over the last 4 years, despite the statements of good intent from central government. Too many patients are suffering strokes, with known risk factors untreated and there are evidently systematic problems in delivering effective universal prevention after stroke, both within the hospital and in primary care. Developments in secondary prevention of stroke since the audit, notably the demonstration of the value of thiazide diuretics, long acting angiotensin converting enzyme inhibitors and statins even in people with blood pressure and lipids within conventionally accepted normal ranges has highlighted the need to improve delivery of preventative treatment [19] . The extent to which the blame lies with the health professionals or the patients could not be ascertained in this study and research is needed to identify where the barriers to effective care are and how to overcome them. Older patients particularly those over the age of 75 years and those with more severe disability after stroke are less likely to receive appropriate secondary prevention and it is these groups that need to be speciWcally targeted in health promotion strategies.
Secondary prevention is an area of care that may be suffering from the split between primary and secondary care in the United Kingdom, with neither party taking responsibility on the assumption that the other is doing it. It is hoped that introduction of targets for secondary prevention in the new General Medical Services contract may focus attention on the delivery of high quality services for all patients.
Levels of patient knowledge and understanding about stroke prevention are low; effective care is unlikely to be achieved without the full cooperation of the patient and carers. This can only be achieved by closer partnerships between patients and health professionals and more effective ways of informing the public about minimisation of risk factors for vascular disease. Considerable resources have been devoted to coronary artery disease prevention, especially for younger patients; risk factor management is similar for cerebrovascular disease and it may be time to combine efforts with the establishment of vascular risk reduction initiatives, rather than running parallel services. For each individual patient after stroke there needs to be clarity as to how and by whom secondary prevention will be delivered and monitored.
Stroke is considerably cheaper to prevent than to treat, both Wnancially and in terms of suffering. Combination primary prevention in the form of a 'Polypill' including antihypertensive treatment, a statin, aspirin and folic acid given to all people over the age of 55 years could reduce stroke by 80% [20] . Such a calculation has not been made for the value of combination secondary prevention, but if the risk reduction was similar, with less than half of stroke patients currently receiving effective treatment to prevent subsequent stroke, then at least 40% of recurrent stroke could be avoided. It is time investment was made both in terms of research and service delivery to transform services in the United Kingdom.
Key points
• A high proportion of people who have a stroke have preexisting untreated cardiovascular risk factors.
• The evidence for primary and secondary prevention of stroke is increasingly strong.
• At follow-up 6 months after stroke a high proportion of patients were without appropriate treatment, or treated risk factors uncontrolled.
• Major opportunities are being missed for both primary and secondary prevention of stroke.
